Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 7/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.33 |
| ▸ | RRM1 | P23921 | 7/20 | 0.33 |
| ▸ | RRM2B | Q7LG56 | 7/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29628526 | 1.00 | CHRM2 (0.33) | CHRM2CHRM1RRM1RRM2BACHE | |
| SCHEMBL29628524 | 1.00 | CHRM2 (0.33) | CHRM2CHRM1RRM1RRM2BACHE | |
| SCHEMBL19682342 | 0.86 | — | — | |
| SCHEMBL19682787 | 0.83 | ACHE (0.31) | ACHE | |
| SCHEMBL9945902 | 0.82 | CHRM2 (0.34) | CHRM2CHRM1RRM1RRM2BACHE | |
| SCHEMBL19682804 | 0.81 | — | — | |
| SCHEMBL19682801 | 0.79 | MET (0.31) | CHRM2CHRM1RRM1RRM2B | |
| SCHEMBL5256194 | 0.79 | P2RX7 (0.33) | — | |
| SCHEMBL29628557 | 0.78 | CHRM2 (0.34) | CHRM2CHRM1RRM1RRM2BACHE | |
| SCHEMBL20872550 | 0.78 | CHRM2 (0.34) | CHRM2CHRM1RRM1RRM2BACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085067-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | BOUNDLESS BIO INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-20250223270-A1 | Sulfonamide Compounds and Use Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-07-10 | — | — | US | disclosed |
| US-12344588-B2 | Sulfonamide compounds and use thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-07-01 | — | — | US | disclosed |
| US-20240425490-A1 | SULFAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-12-26 | — | — | US | disclosed |
| EP-4402134-A1 | SULFAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | Boundless Bio, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-4401728-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | Boundless Bio, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| CN-111386260-B | Sulfonamide compounds and uses thereof | 大鹏药品工业株式会社 | 2024-04-30 | — | — | CN | disclosed |
| EP-3466934-B1 | SULFONAMIDE COMPOUNDS OR SALT THEREOF AS RIBONUCLEOTIDE REDUCTASE INHIBITORS FOR TREATING CANCER | TAIHO PHARMACEUTICAL CO LTD (JP) | 2024-03-27 | — | — | EP | disclosed |
| EP-3717462-B1 | CO-CRYSTAL OF BENZOIC ACID AND SULFONAMIDE COMPOUND FOR THE TREATMENT OF TUMORS | TAIHO PHARMACEUTICAL CO LTD (JP) | 2024-01-03 | — | — | EP | disclosed |
| US-11634395-B2 | Sulfonamide compound or salt thereof | Taiho Pharmaceutial Co., Ltd. (JP) | 2023-04-25 | — | — | US | disclosed |
| US-20200361883-A1 | Sulfonamide Compounds and Use Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-11-19 | — | — | US | disclosed |
| EP-3717462-A1 | SULFONAMIDE COMPOUNDS AND USE THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-10-07 | — | — | EP | disclosed |
| EP-3718545-A1 | ANTITUMOR AGENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-10-07 | — | — | EP | disclosed |
| EP-3718545-A1 | ANTITUMOR AGENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-10-07 | — | — | EP | disclosed |
| CN-111386260-A | Sulfonamide compound and use thereof | 大鹏药品工业株式会社 | 2020-07-07 | — | — | CN | disclosed |
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-05-21 | — | — | US | disclosed |
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-05-21 | — | — | US | disclosed |
| EP-3466934-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2019-04-10 | — | — | EP | disclosed |
| EP-3466934-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017209155-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | 大鵬薬品工業株式会社 | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | RNASEH1, SNRPA1, RRM2 | CHRM2 4302/4885CHRM1 4399/4885RRM1 5/4885 |
| US-20200361883-A1 | Sulfonamide Compounds and Use Thereof | STS, SULT2A1, TPST2 | CHRM2 3967/4885CHRM1 4710/4885RRM1 95/4885 |
| US-20260085067-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | RRM1, RRM2B, RRM2 | CHRM2 3695/4885CHRM1 3732/4885RRM1 1/4885 |
| US-20240425490-A1 | SULFAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | RRM2B, RRM2, RRM1 | CHRM2 4880/4885CHRM1 4885/4885RRM1 3/4885 |
| US-20250223270-A1 | Sulfonamide Compounds and Use Thereof | STS, SULT2A1, TPST2 | CHRM2 3967/4885CHRM1 4710/4885RRM1 95/4885 |
| US-12344588-B2 | Sulfonamide compounds and use thereof | STS, SULT2A1, TPST2 | CHRM2 3967/4885CHRM1 4710/4885RRM1 95/4885 |
| US-11634395-B2 | Sulfonamide compound or salt thereof | RNASEH1, SNRPA1, RRM2 | CHRM2 4302/4885CHRM1 4399/4885RRM1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.